The AGNP-TDM expert group consensus guidelines:: Therapeutic Drug Monitoring in psychiatry

被引:397
作者
Baumann, P
Hiemke, C
Ulrich, S
Eckermann, G
Gaertner, I
Gerlach, M
Kuss, HJ
Laux, G
Müller-Oerlinghausen, B
Rao, ML
Riederer, P
Zernig, G
机构
[1] Univ Lausanne, Dept Psychiat, Lausanne, Switzerland
[2] Johannes Gutenberg Univ Mainz, Dept Psychiat, D-6500 Mainz, Germany
[3] Univ Magdeburg, Dept Clin Pharmacol, D-39106 Magdeburg, Germany
[4] Bezirkskrankenhaus Kaufbeuren, Kaufbeuren, Germany
[5] Univ Tubingen, Dept Psychiat, D-72074 Tubingen, Germany
[6] Univ Wurzburg, Dept Child & Adolescent Psychiat, D-97070 Wurzburg, Germany
[7] Univ Munich, Dept Psychiat, D-80539 Munich, Germany
[8] Bezirksklinikum Gabersee, Wasserburg, Germany
[9] Drug Commiss German Med Assoc, Berlin, Germany
[10] Drug Commiss German Med Assoc, Cologne, Germany
[11] Univ Bonn, Dept Psychiat, D-5300 Bonn, Germany
[12] Univ Wurzburg, Dept Psychiat, D-8700 Wurzburg, Germany
[13] Univ Innsbruck, Dept Psychiat, A-6020 Innsbruck, Austria
关键词
D O I
10.1055/s-2004-832687
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Therapeutic Drug Monitoring (TDM) is a valid tool to optimise pharmacotherapy. It enables the clinician to adjust the dosage of drugs according to the characteristics of the individual patient. In psychiatry, TDM is an established procedure for lithium, some antidepressants and antipsychotics. In spite of its obvious advantages, however, the use of TDM in everyday clinical practice is far from optimal. The interdisciplinary TDM group of the Arbeitsgemeinschaft fur Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) has therefore worked out consensus guidelines to assist psychiatrists and laboratories involved in psychotropic drug analysis to optimise the use of TDM of psychotropic drugs. Five research-based levels of recommendation were defined with regard to routine monitoring of plasma concentrations for dose titration of 65 psychoactive drugs: (1) strongly recommended, (2) recommended, (3) useful, (4) probably useful and (5) not recommended. A second approach defined indications to use TDM, e.g. control of compliance, lack of clinical response or adverse effects at recommended doses, drug interactions, pharma-covigilance programs, presence of a genetic particularity concerning the drug metabolism, children, adolescents and elderly patients. Indications for TDM are relevant for all drugs either with or without validated therapeutic ranges. When studies on therapeutic ranges are lacking, target ranges should be plasma concentrations that are normally observed at therapeutic doses of the drug. Therapeutic ranges of plasma concentrations that are considered to be optimal for treatment are proposed for those drugs, for which the evaluation of the literature demonstrated strong evidence. Moreover, situations are defined when pharmacogenetic (phenotyping or genotyping) tests are informative in addition to TDM. Finally, practical instructions are given how to use TDM. They consider preparation of TDM, analytical procedures, reporting and interpretation of results and the use of information for patient treatment. Using the consensus guideline will help to ensure optimal clinical benefit of TDM in psychiatry.
引用
收藏
页码:243 / 265
页数:23
相关论文
共 279 条
[31]   Ziprasidone metabolism, aldehyde oxidase, and clinical implications [J].
Beedham, C ;
Miceli, JJ ;
Obach, RS .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (03) :229-232
[32]   Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone [J].
Beelen, AP ;
Yeo, KTJ ;
Lewis, LD .
HUMAN & EXPERIMENTAL TOXICOLOGY, 2001, 20 (04) :215-219
[33]  
Benet L.Z., 1996, GOODMAN GILMANS PHAR, V3, P27
[34]   Therapeutic drug monitoring of psychotropic drugs - TDM "Nouveau" [J].
Bengtsson, F .
THERAPEUTIC DRUG MONITORING, 2004, 26 (02) :145-151
[35]   Plasma amisulpride levels in schizophrenia or schizoaffective disorder [J].
Bergemann, N ;
Kopitz, J ;
Kress, KR ;
Frick, A .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 (03) :245-250
[36]  
BERTILSSON L, 1981, LANCET, V1, P560
[37]   Polymorphic drug oxidation - Relevance to the treatment of psychiatric disorders [J].
Bertilsson, L ;
Dahl, ML .
CNS DRUGS, 1996, 5 (03) :200-223
[38]   RELATIONSHIP BETWEEN CLINICAL EFFECTS, SERUM DRUG CONCENTRATION AND SEROTONIN UPTAKE INHIBITION IN DEPRESSED-PATIENTS TREATED WITH CITALOPRAM - A DOUBLE-BLIND COMPARISON OF 3 DOSE LEVELS [J].
BJERKENSTEDT, L ;
FLYCKT, L ;
OVERO, KF ;
LINGJAERDE, O .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 28 (05) :553-557
[39]   HIGH DOSAGE HALOPERIDOL THERAPY IN CHRONIC-SCHIZOPHRENIC PATIENTS - DOUBLE-BLIND-STUDY OF CLINICAL-RESPONSE, SIDE-EFFECTS, SERUM HALOPERIDOL, AND SERUM PROLACTIN [J].
BJORNDAL, N ;
BJERRE, M ;
GERLACH, J ;
KRISTJANSEN, P ;
MAGELUND, G ;
OESTRICH, IH ;
WAEHRENS, J .
PSYCHOPHARMACOLOGY, 1980, 67 (01) :17-23
[40]   Non response to citalopram in depressive patients: Pharmacokinetic and clinical consequences of a fluvoxamine augmentation [J].
Bondolfi, G ;
Chautems, C ;
Rochat, B ;
Bertschy, G ;
Baumann, P .
PSYCHOPHARMACOLOGY, 1996, 128 (04) :421-425